Physicians' Academy for Cardiovascular Education

Need for ongoing clinical innovation in management of T2DM: A closer look at the development process of new entities

Lecture - July 30, 2016 - Asian Interchange on Diabetes meeting - Michael Mark, MD, Boehringer Ingelheim – Cardiometabolic Diseases Research

Michael Mark illustrates the full trajectory of development of the SGLT2 inhibitor empagliflozin, from finding a therapeutic target through testing clinical effects of the newly developed therapeutic agent.

This lecture was recorded at the Asian Interchange on Diabetes meeting, held in Bangkok on July 30-31, 2016.

Video navigation menu

  • Why do we need ongoing clinical innovation for the management of T2DM? 0:21
  • The drug discovery and development process is a long and challenging trajectory 3:43
  • Discovery of the SGLT2 transporter as a therapeutic target and finding an inhibitor 6:50
  • Testing the identified compound and developing a drug 13:34
  • Results of the phase I, II and III trials evaluating a SGLT2 inhibitor 16:35
  • Meeting unmet needs in diabetes care: is that enough? 20:07

The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: